Citigroup’s Orgenesis Inc. Common Stock ORGS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-126
| Closed | -$562 | – | 6045 |
|
|
2024
Q3 | $562 | Buy |
+126
| New | +$840 | ﹤0.01% | 5474 |
|
|
2021
Q2 | – | Sell |
-125
| Closed | -$7K | – | 6464 |
|
|
2021
Q1 | $7K | Sell |
125
-216
| -63% | -$14.1K | ﹤0.01% | 5820 |
|
|
2020
Q4 | $15K | Buy |
341
+254
| +292% | +$12.2K | ﹤0.01% | 6806 |
|
|
2020
Q3 | $4K | Sell |
87
-145
| -63% | -$7.86K | ﹤0.01% | 7159 |
|
|
2020
Q2 | $14K | Buy |
+232
| New | +$14K | ﹤0.01% | 6875 |
|
|
2019
Q1 | – | Sell |
-50
| Closed | -$2K | – | 7852 |
|
|
2018
Q4 | $2K | Sell |
50
-80
| -62% | -$4.6K | ﹤0.01% | 7526 |
|
|
2018
Q3 | $7K | Hold |
130
| – | – | ﹤0.01% | 7445 |
|
|
2018
Q2 | $11K | Hold |
130
| – | – | ﹤0.01% | 7161 |
|
|
2018
Q1 | $13K | Buy |
+130
| New | +$15.4K | ﹤0.01% | 6947 |
|
Citigroup's ORGS Position: Q4 2024 in Review
Citigroup sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2024, closing a stake of 126 shares — an estimated $562 sold.
Citigroup first reported a position in ORGS in Q1 2018 and held it in 9 quarters. The position peaked at $15K in Q4 2020. 0 funds tracked by Wall St. Rank hold ORGS as of Q4 2024.
- Citigroup reported no remaining Orgenesis Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Citigroup sold 126 Orgenesis Inc. Common Stock shares in Q4 2024, an estimated $562.
- Citigroup first reported a position in Orgenesis Inc. Common Stock in Q1 2018 and held it in 9 quarters.
- Citigroup's Orgenesis Inc. Common Stock position peaked at $15K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2024.
Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.